Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
Authors
Keywords
-
Journal
Pharmacology Research & Perspectives
Volume 9, Issue 2, Pages -
Publisher
Wiley
Online
2021-03-21
DOI
10.1002/prp2.757
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Follow up survey for implementation of fixed-dosing of monoclonal antibodies
- (2020) Kimberley M. Heinhuis et al. International Journal of Clinical Pharmacy
- Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center
- (2020) Evan Hall et al. Cancer Medicine
- The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
- (2020) Thierry Buclin et al. Frontiers in Pharmacology
- Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy
- (2020) Hansoo Kim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments
- (2020) Dinusha T. Vithanachchi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations
- (2020) Florent Ferrer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
- (2020) Naoya Yamazaki et al. JOURNAL OF DERMATOLOGY
- Hypoalbuminemia Reflects Nutritional Risk, Body Composition and Systemic Inflammation and Is Independently Associated with Survival in Patients with Colorectal Cancer
- (2020) Arwa S. Almasaudi et al. Cancers
- Bottom-up sample preparation for the LC–MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices
- (2020) Karen AM de Jong et al. Bioanalysis
- Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
- (2019) Edwin A. Basak et al. EUROPEAN JOURNAL OF CANCER
- Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
- (2019) Maddalena Centanni et al. CLINICAL PHARMACOKINETICS
- Cetuximab Pharmacokinetic/Pharmacodynamics relationships in advanced head and neck carcinoma patients.
- (2019) Félicien Le Louedec et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Neonatal Fc Receptor: Key to Homeostasic Control of IgG and IgG‐Related Biopharmaceuticals
- (2019) William M. Baldwin et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience.
- (2019) Manuel Sureda et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
- (2019) Kari M. Morrissey et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
- (2019) Bellesoeur et al. Cancers
- Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
- (2018) David Turner et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- (2018) Paul G. Baverel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
- (2018) Anders H. Kverneland et al. OncoImmunology
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- Time Is Money: Optimizing the Scheduling of Nivolumab
- (2018) Mark J. Ratain et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties
- (2018) Chiyo K. Imamura Drug Metabolism and Pharmacokinetics
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study
- (2017) Luc Cabel et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- (2017) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
- (2017) Jennifer Sheng et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Fixed Dosing of Monoclonal Antibodies in Oncology
- (2017) Jeroen J.M.A. Hendrikx et al. ONCOLOGIST
- Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
- (2016) Morgane Caulet et al. CLINICAL PHARMACOKINETICS
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology
- (2015) TH Oude Munnink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial
- (2014) V. Gotta et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
- (2014) Valérie F. Cosson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
- (2014) Nicolas Widmer et al. EUROPEAN JOURNAL OF CANCER
- Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- (2013) Y. Feng et al. CLINICAL CANCER RESEARCH
- Without Therapeutic Drug Monitoring, There Is No Personalized Cancer Care
- (2013) J H Beumer CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
- (2012) E Chatelut et al. BRITISH JOURNAL OF CANCER
- A Guide to Rational Dosing of Monoclonal Antibodies
- (2012) Shuang Bai et al. CLINICAL PHARMACOKINETICS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
- (2011) N. Azzopardi et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies
- (2010) Diane R. Mould et al. BIODRUGS
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
- (2009) Diane D. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now